Tumor-Associated Antigen Preferentially Expressed Antigen of Melanoma (PRAME) Induces Caspase-Independent Cell Death In vitro and Reduces Tumorigenicity In vivo
Authors:
Open Access
- 15 August 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (16) , 7348-7355
Abstract
Preferentially expressed antigen of melanoma (PRAME) is expressed in a wide variety of tumors, but in contrast with most other tumor associated antigens, it is also expressed in leukemias. The physiologic role of PRAME remains elusive. Interestingly, PRAME expression is correlated with a favorable prognosis in childhood acute leukemias. Moreover, a high expression of PRAME seems to be predominantly found in acute leukemias carrying a favorable prognosis. On these clinical observations, we assumed that PRAME could be involved in the regulation of cell death or cell cycle. In this study, we show that transient overexpression of PRAME induces a caspase-independent cell death in cultured cell lines (CHO-K1 and HeLa). Cells stably transfected with PRAME also exhibit a decreased proliferation rate due, at least partially, to an elevated basal rate of cell death. Immunocytochemistry of a FLAG-tagged PRAME, in vivo imaging of an enhanced green fluorescent protein–tagged PRAME, and Western blotting after cell fractionation reveal a nuclear localization of the protein. Using a microarray-based approach, we show that KG-1 leukemic cells stably transfected with PRAME present a significant decrease of expression of the heat-shock protein Hsp27, the cyclin-dependent kinase inhibitor p21, and the calcium-binding protein S100A4. The expression of these three proteins is known to inhibit apoptosis and has been associated with an unfavorable prognosis in a series of cancers. Finally, repression of PRAME expression by a short interfering RNA strategy increases tumorigenicity of K562 leukemic cells in nude mice. We suggest that all these observations might explain the favorable prognosis of the leukemias expressing high levels of PRAME.Keywords
This publication has 18 references indexed in Scilit:
- A listing of human tumor antigens recognized by T cells: March 2004 updateCancer Immunology, Immunotherapy, 2004
- The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemiaCritical Reviews in Oncology/Hematology, 2004
- mRNA expression of leukemia‐associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapiesInternational Journal of Cancer, 2003
- Constitutive cytoplasmic localization of p21Waf1/Cip1 affects the apoptotic process in monocytic leukaemiaLeukemia, 2003
- Protein S100A4: Too Long Overlooked by Pathologists?The American Journal of Pathology, 2002
- Tumor Suppressor p53 Protein Is a New Target for the Metastasis-associated Mts1/S100A4 ProteinJournal of Biological Chemistry, 2001
- PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cellsBritish Journal of Haematology, 1998
- Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory ReceptorImmunity, 1997
- Induction of 18A2/mts1 Gene Expression and Its Effects on Metastasis and Cell Cycle ControlDNA and Cell Biology, 1994
- Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family.Genes & Development, 1989